These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
330 related articles for article (PubMed ID: 26072332)
1. Expression of the ETS transcription factor GABPα is positively correlated to the BCR-ABL1/ABL1 ratio in CML patients and affects imatinib sensitivity in vitro. Manukjan G; Ripperger T; Santer L; von Neuhoff N; Ganser A; Schambach A; Schlegelberger B; Steinemann D Exp Hematol; 2015 Oct; 43(10):880-90. PubMed ID: 26072332 [TBL] [Abstract][Full Text] [Related]
2. GABP transcription factor is required for development of chronic myelogenous leukemia via its control of PRKD2. Yang ZF; Zhang H; Ma L; Peng C; Chen Y; Wang J; Green MR; Li S; Rosmarin AG Proc Natl Acad Sci U S A; 2013 Feb; 110(6):2312-7. PubMed ID: 23345428 [TBL] [Abstract][Full Text] [Related]
3. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy. Ferri C; Bianchini M; Bengió R; Larripa I Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144 [TBL] [Abstract][Full Text] [Related]
4. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation. Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872 [TBL] [Abstract][Full Text] [Related]
5. MXD1 regulates the imatinib resistance of chronic myeloid leukemia cells by repressing BCR-ABL1 expression. Huan C; Jin L; Heng W; Na A; Yuming P; Xin D; Qiaoxia Z Leuk Res; 2018 Dec; 75():1-6. PubMed ID: 30419548 [TBL] [Abstract][Full Text] [Related]
7. BCR-ABL1 tyrosine kinase sustained MECOM expression in chronic myeloid leukaemia. Roy S; Jørgensen HG; Roy P; Abed El Baky M; Melo JV; Strathdee G; Holyoake TL; Bartholomew C Br J Haematol; 2012 May; 157(4):446-56. PubMed ID: 22372463 [TBL] [Abstract][Full Text] [Related]
8. System analysis of Huang-Lian-Jie-Du-Tang and their key active ingredients for overcoming CML resistance by suppression of leukemia stem cells. Huang G; Yin Z; Wang X; Wen Z; Su R; Li C; Liu Y; Yang J; Hu H; Nie H; Zeng X; Fei J Phytomedicine; 2023 Aug; 117():154918. PubMed ID: 37329755 [TBL] [Abstract][Full Text] [Related]
9. UV Differentially Induces Oxidative Stress, DNA Damage and Apoptosis in BCR-ABL1-Positive Cells Sensitive and Resistant to Imatinib. Synowiec E; Hoser G; Wojcik K; Pawlowska E; Skorski T; Błasiak J Int J Mol Sci; 2015 Aug; 16(8):18111-28. PubMed ID: 26251899 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of isoprenylcysteine carboxylmethyltransferase augments BCR-ABL1 tyrosine kinase inhibition-induced apoptosis in chronic myeloid leukemia. Sun WT; Xiang W; Ng BL; Asari K; Bunte RM; Casey PJ; Wang M; Chuah C Exp Hematol; 2016 Mar; 44(3):189-93.e2. PubMed ID: 26706195 [TBL] [Abstract][Full Text] [Related]
11. Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors. Mancini M; De Santis S; Monaldi C; Bavaro L; Martelli M; Castagnetti F; Gugliotta G; Rosti G; Santucci MA; Martinelli G; Cavo M; Soverini S J Exp Clin Cancer Res; 2019 May; 38(1):216. PubMed ID: 31122263 [TBL] [Abstract][Full Text] [Related]
12. The chimeric ubiquitin ligase SH2-U-box inhibits the growth of imatinib-sensitive and resistant CML by targeting the native and T315I-mutant BCR-ABL. Ru Y; Wang Q; Liu X; Zhang M; Zhong D; Ye M; Li Y; Han H; Yao L; Li X Sci Rep; 2016 Jun; 6():28352. PubMed ID: 27329306 [TBL] [Abstract][Full Text] [Related]
13. Contributions of MET activation to BCR-ABL1 tyrosine kinase inhibitor resistance in chronic myeloid leukemia cells. Tsubaki M; Takeda T; Kino T; Sakai K; Itoh T; Imano M; Nakayama T; Nishio K; Satou T; Nishida S Oncotarget; 2017 Jun; 8(24):38717-38730. PubMed ID: 28418880 [TBL] [Abstract][Full Text] [Related]
16. Characteristics of the TCR Vβ repertoire in imatinib-resistant chronic myeloid leukemia patients with ABL mutations. Xu L; Lu Y; Lai J; Yu W; Zhang Y; Jin Z; Xu Y; Chen J; Zha X; Chen S; Yang L; Li Y Sci China Life Sci; 2015 Dec; 58(12):1276-81. PubMed ID: 26423566 [TBL] [Abstract][Full Text] [Related]
17. Bcr-Abl expression levels determine the rate of development of resistance to imatinib mesylate in chronic myeloid leukemia. Barnes DJ; Palaiologou D; Panousopoulou E; Schultheis B; Yong AS; Wong A; Pattacini L; Goldman JM; Melo JV Cancer Res; 2005 Oct; 65(19):8912-9. PubMed ID: 16204063 [TBL] [Abstract][Full Text] [Related]
18. Detection of BCR-ABL1 kinase domain mutations causing imatinib resistance in chronic myelogenous leukemia. Moore FR; Yang F; Press RD Methods Mol Biol; 2013; 999():25-39. PubMed ID: 23666688 [TBL] [Abstract][Full Text] [Related]
19. Overexpression of Deng Y; Li X; Feng J; Zhang X Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29559564 [TBL] [Abstract][Full Text] [Related]
20. WT1-mediated repression of the proapoptotic transcription factor ZNF224 is triggered by the BCR-ABL oncogene. Montano G; Vidovic K; Palladino C; Cesaro E; Sodaro G; Quintarelli C; De Angelis B; Errichiello S; Pane F; Izzo P; Grosso M; Gullberg U; Costanzo P Oncotarget; 2015 Sep; 6(29):28223-37. PubMed ID: 26320177 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]